Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination

@article{Coleman2016HumanPT,
  title={Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination},
  author={Hannah N. Coleman and William W. Greenfield and Shawna L. Stratton and Rita Vaughn and Alexander Kieber and Andrea M. Moerman-Herzog and Horace J. Spencer and Wilbur. C. Hitt and Charles Quick and Laura Hutchins and Samuel G. Mackintosh and Ricky D. Edmondson and Stephen W. Erickson and Mayumi Nakagawa},
  journal={Cancer Immunology, Immunotherapy},
  year={2016},
  volume={65},
  pages={563-573}
}
In the dose-escalation phase of a Phase I clinical trial in which six subjects each were vaccinated with PepCan at the 50, 100, 250, and 500 μg per peptide dose, the 50 μg dose showed the best histological regression rate. Ten additional subjects were vaccinated at this dose in the final dose phase. As with the dose-escalation phase, no dose-limiting toxicities were observed. Overall, the histological regression rates were 50 % at the 50 μg dose (7 of 14) and 100 μg dose (3 of 6), and 45… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 6 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Beyond cervical cancer: burden of other HPV-related cancers among men and women.

The Journal of adolescent health : official publication of the Society for Adolescent Medicine • 2010

Similar Papers

Loading similar papers…